The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications
Abstract
Background Postmortem and in vivo imaging data support the hypothesis that premature myelin breakdown and subsequent homeostatic remyelination attempts with increased oligodendrocyte and iron levels may contribute to Huntington's Disease (HD) pathogenesis and the symmetrical progress of neuronal loss from earlier-myelinating striatum to later-myelinating regions. A unique combination of in vivo tissue integrity and iron level assessments was used to examine the hypothesis.Methods A method that uses two Magnetic resonance imaging (MRI) instruments operating at different field-strengths was used to quantify the iron content of ferritin molecules (ferritin iron) as well as tissue integrity in eight regions in 11 HD and a matched group of 27 healthy control subjects. Three white matter regions were selected based on their myelination pattern (early to later-myelinating) and fiber composition. These were frontal lobe white matter (Fwm) and splenium and genu of the corpus callosum (Swm and Gwm). In addition, gray matter structures were also chosen based on their myelination pattern and fiber composition. Three striatum structures were assessed [caudate, putamen, and globus pallidus (C, P, and G)] as well as two comparison gray matter regions that myelinate later in development and are relatively spared in HD [Hippocampus (Hipp) and Thalamus (Th)].Results Compared to healthy controls, HD ferritin iron levels were significantly increased in striatum C, P, and G, decreased in Fwm and Gwm, and were unchanged in Hipp, Th, and Swm. Loss of tissue integrity was observed in C, P, Fwm, and especially Swm but not Hipp, Th, G, or Gwm. This pattern of findings was largely preserved when a small subset of HD subjects early in the disease process was examined.Conclusions The data suggest early in the HD process, myelin breakdown and changes in ferritin iron distribution underlie the pattern of regional toxicity observed in HD. Prospective studies are needed to verify myelin breakdown and increased iron levels are causal factors in HD pathogenesis. Tracking the effects of novel interventions that reduce myelin breakdown and iron accumulation in preclinical stages of HD could hasten the development of preventive treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in brain iron metabolism with increased iron accumulation were identified by MRI in the striata of patients with Huntington’s disease194 and in particular the basal ganglia (caudate nucleus, putamen, and globus pallidus).195,196”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [194]
Citations
Cites
Tests for comparing elements of a correlation matrix
Steiger, J. H. (1980) · Psychological Bulletin · doi:10.1037/0033-2909.87.2.245 · Cited by 4,621 · cited 1×
“were performed using Hotelling’s statistic [60], a test for the difference between two non-independent correlations [61].”
MethodWalker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,691
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Regional Development of the Brain in Early Life
(1968) · Archives of Disease in Childhood · doi:10.1136/adc.43.229.388 · Cited by 2,107
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Vonsattel, J. P., & DiFiglia, M. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199805000-00001 · Cited by 1,305
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968
Self-citation
Flagged first, then by citations
1 of the 94 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Harper PS, Shaw D (1996) Huntington’s disease: genetic and molecular studies. In: Harper PS (eds) Huntington’s disease 2nd edn. W.B.Saunders, Philadelphia, pp 241–293
- Jones AL (1996) The Huntington’s disease gene and its protein product. In: Harper PS (eds) Huntington’s disease, 2 edn. W.B.Saunders, Philadelphia, pp 293–316
- Bruyn GW (1973) Neuropathological changes in Huntington’s chorea. In: Barbeau A, Chase TN, Paulson GW (eds) Huntington’s Chorea, vol 1. Raven Press, New York, pp 399–403
- Liss L, Paulson GW, Sommer A (1973) Rigid form of Huntington’s chorea: a clinicopathological study of three cases. In: Barbeau A, Chase TN, Paulson GW (eds) Huntington’s Chorea, vol 1. Raven Press, New York, pp 405–424
- Klintworth GK (1973) Huntington’s chorea—morphologic contributions of a century. In: Barbeau A, Paulson GW, Chase TN (eds) Advances in neurology. Huntington’s chorea, vol 1. 1872–1972. Raven Press, New York, pp 353–368
Cited by
Sorted by citations
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Oligodendrocytes and myelination: The role of iron
Todorich, B., Pasquini, J. M., Garcia, C. I., Paez, P. M., & Connor, J. R. (2008) · Glia · doi:10.1002/glia.20784 · Cited by 615
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 594
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
Self-citationMRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping
Bilgic, B., Pfefferbaum, A., Rohlfing, T., Sullivan, E. V., & Adalsteinsson, E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.08.077 · Cited by 499
Metadata
- Authors
- Bartzokis, G., Lu, P. H., Tishler, T. A., Fong, S. M., Oluwadara, B., Finn, J. P., Huang, D., Bordelon, Y., Mintz, J., & Perlman, S.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Bartzokis, George
- Venue
- Neurochemical Research
- Published
- 2007-05-05
- Volume
- 32
- Issue
- 10
- Pages
- 1655-1664
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W1986646115
- Cited by
- 238
- References
- 94
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 11 · 2019: 14 · 2018: 14 · 2017: 10 · 2016: 9 · 2015: 24 · 2014: 16 · 2013: 18 · 2012: 18
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neurochemical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5r03mh051928-02)
- National Institute on Aging (R01AG027342, P50AG016570, AG 16570)
- National Institute of Mental Health (MH6357-01A1, MH 51928, MH066029-01A2, R01MH066029)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Keywords
- Huntington's disease, myelin breakdown, tissue integrity, remyelination, oligodendrocytes, striatum, corpus callosum, white matter, pathogenesis, preclinical disease, iron accumulation, MRI field strength
- MeSH terms
- Adult, Aged, Brain, Brain Chemistry, Data Interpretation, Statistical, Female, Ferritins, Humans, Huntington Disease, Image Processing, Computer-Assisted, Iron, Magnetic Resonance Imaging, Male, Middle Aged, Myelin Sheath
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review